<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339949</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Multiplex Microscopy Assay for Assessment of Therapeutic and Serum Antibodies against Emerging Pathogens.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1473</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091473</ELocationID><Abstract><AbstractText>The emergence of novel pathogens, exemplified recently by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlights the need for rapidly deployable and adaptable diagnostic assays to assess their impact on human health and guide public health responses in future pandemics. In this study, we developed an automated multiplex microscopy assay coupled with machine learning-based analysis for antibody detection. To achieve multiplexing and simultaneous detection of multiple viral antigens, we devised a barcoding strategy utilizing a panel of HeLa-based cell lines. Each cell line expressed a distinct viral antigen, along with a fluorescent protein exhibiting a unique subcellular localization pattern for cell classification. Our robust, cell segmentation and classification algorithm, combined with automated image acquisition, ensured compatibility with a high-throughput approach. As a proof of concept, we successfully applied this approach for quantitation of immunoreactivity against different variants of SARS-CoV-2 spike and nucleocapsid proteins in sera of patients or vaccinees, as well as for the study of selective reactivity of monoclonal antibodies. Importantly, our system can be rapidly adapted to accommodate other SARS-CoV-2 variants as well as any antigen of a newly emerging pathogen, thereby representing an important resource in the context of pandemic preparedness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sartingen</LastName><ForeName>Nuno</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stürmer</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaltenböck</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Thorsten G</ForeName><Initials>TG</Initials><Identifier Source="ORCID">0000-0002-4197-6224</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schnitzler</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreshuk</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>European Molecular Biology Laboratory, 69117 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kräusslich</LastName><ForeName>Hans-Georg</ForeName><Initials>HG</Initials><Identifier Source="ORCID">0000-0002-8756-329X</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Heidelberg, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merle</LastName><ForeName>Uta</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0003-1386-3350</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine IV, University Hospital Heidelberg, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mücksch</LastName><ForeName>Frauke</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-0132-5101</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-5726-5585</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pape</LastName><ForeName>Constantin</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-6562-7187</Identifier><AffiliationInfo><Affiliation>Institute of Computer Science, Göttingen University, 37073 Göttingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence 'Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells' (MBExC), Göttingen University, 37073 Göttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laketa</LastName><ForeName>Vibor</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-9472-2738</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Virology, Medical Faculty Heidelberg, Heidelberg University, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Heidelberg, 69120 Heidelberg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TTU 04.710</GrantID><Agency>German Center for Infection Research</Agency><Country /></Grant><Grant><GrantID>EXC 2067/1- 390729940</GrantID><Agency>Deutsche Forschungsgemeinschaft</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086462">Coronavirus Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000705834">nucleocapsid phosphoprotein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010750">Phosphoproteins</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008853" MajorTopicYN="N">Microscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086462" MajorTopicYN="N">Coronavirus Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010750" MajorTopicYN="N">Phosphoproteins</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">emerging pathogens</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">monoclonal antibodies</Keyword><Keyword MajorTopicYN="N">multiplex microscopy</Keyword><Keyword MajorTopicYN="N">serology</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339949</ArticleId><ArticleId IdType="pmc">PMC11437451</ArticleId><ArticleId IdType="doi">10.3390/v16091473</ArticleId><ArticleId IdType="pii">v16091473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2001017</ArticleId><ArticleId IdType="pmc">PMC7092803</ArticleId><ArticleId IdType="pubmed">31978945</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemente-Suarez V.J., Dalamitros A.A., Beltran-Velasco A.I., Mielgo-Ayuso J., Tornero-Aguilera J.F. Social and Psychophysiological Consequences of the COVID-19 Pandemic: An Extensive Literature Review. Front. Psychol. 2020;11:580225. doi: 10.3389/fpsyg.2020.580225.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyg.2020.580225</ArticleId><ArticleId IdType="pmc">PMC7772398</ArticleId><ArticleId IdType="pubmed">33391099</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed F., Shafer L., Malla P., Hopkins R., Moreland S., Zviedrite N., Uzicanin A. Systematic review of empiric studies on lockdowns, workplace closures, and other non-pharmaceutical interventions in non-healthcare workplaces during the initial year of the COVID-19 pandemic: Benefits and selected unintended consequences. BMC Public Health. 2024;24:884. doi: 10.1186/s12889-024-18377-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-024-18377-1</ArticleId><ArticleId IdType="pmc">PMC10960383</ArticleId><ArticleId IdType="pubmed">38519891</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadeh H., Sharifi A., Damanbagh S., Nazarnia H., Nazarnia M. Impacts of the COVID-19 pandemic on the social sphere and lessons for crisis management: A literature review. Nat. Hazards. 2023;117:2139–2164. doi: 10.1007/s11069-023-05959-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11069-023-05959-2</ArticleId><ArticleId IdType="pmc">PMC10088618</ArticleId><ArticleId IdType="pubmed">37360799</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford H. US authorization of first COVID vaccine marks new phase in safety monitoring. Nature. 2020;588:377–378. doi: 10.1038/d41586-020-03542-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-03542-4</ArticleId><ArticleId IdType="pubmed">33311629</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586:594–599. doi: 10.1038/s41586-020-2814-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2814-7</ArticleId><ArticleId IdType="pubmed">32998157</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization  WHO Coronavirus (COVID-19) Dashboard.  [(accessed on 15 July 2024)]; Available online:  https://data.who.int/dashboards/covid19/vaccines?n=c.</Citation></Reference><Reference><Citation>Mlcochova P., Kemp S.A., Dhar M.S., Papa G., Meng B., Ferreira I., Datir R., Collier D.A., Albecka A., Singh S., et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature. 2021;599:114–119. doi: 10.1038/s41586-021-03944-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03944-y</ArticleId><ArticleId IdType="pmc">PMC8566220</ArticleId><ArticleId IdType="pubmed">34488225</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S., Jackson L., Khoury D.S., Khan K., Moyo-Gwete T., Tegally H., San J.E., Cromer D., Scheepers C., Amoako D.G., et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602:654–656. doi: 10.1038/s41586-021-04387-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04387-1</ArticleId><ArticleId IdType="pmc">PMC8866126</ArticleId><ArticleId IdType="pubmed">35016196</ArticleId></ArticleIdList></Reference><Reference><Citation>Servellita V., Syed A.M., Morris M.K., Brazer N., Saldhi P., Garcia-Knight M., Sreekumar B., Khalid M.M., Ciling A., Chen P.Y., et al. Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants. Cell. 2022;185:1539–1548.e5. doi: 10.1016/j.cell.2022.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.03.019</ArticleId><ArticleId IdType="pmc">PMC8930394</ArticleId><ArticleId IdType="pubmed">35429436</ArticleId></ArticleIdList></Reference><Reference><Citation>Schäfer A., Muecksch F., Lorenzi J.C.C., Leist S.R., Cipolla M., Bournazos S., Schmidt F., Gazumyan A., Baric R.S., Robbiani D.F., et al. Antibody potency, effector function and combinations in protection from SARS-CoV-2 infection in vivo. bioRxiv. 2020:preprints</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673958</ArticleId><ArticleId IdType="pubmed">33211088</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuccori M., Ferraro S., Convertino I., Cappello E., Valdiserra G., Blandizzi C., Maggi F., Focosi D. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: Clinical pipeline. MAbs. 2020;12:1854149. doi: 10.1080/19420862.2020.1854149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19420862.2020.1854149</ArticleId><ArticleId IdType="pmc">PMC7755170</ArticleId><ArticleId IdType="pubmed">33319649</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Wang J., Jian F., Xiao T., Song W., Yisimayi A., Huang W., Li Q., Wang P., An R., et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657–663. doi: 10.1038/s41586-021-04385-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Bruel T., Staropoli I., Guivel-Benhassine F., Porrot F., Maes P., Grzelak L., Prot M., Mougari S., Planchais C., et al. Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies. Nat. Commun. 2023;14:824. doi: 10.1038/s41467-023-36561-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36561-6</ArticleId><ArticleId IdType="pmc">PMC9926440</ArticleId><ArticleId IdType="pubmed">36788246</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Veyer D., Baidaliuk A., Staropoli I., Guivel-Benhassine F., Rajah M.M., Planchais C., Porrot F., Robillard N., Puech J., et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596:276–280. doi: 10.1038/s41586-021-03777-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03777-9</ArticleId><ArticleId IdType="pubmed">34237773</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollan M., Perez-Gomez B., Pastor-Barriuso R., Oteo J., Hernan M.A., Perez-Olmeda M., Sanmartin J.L., Fernandez-Garcia A., Cruz I., Fernandez de Larrea N., et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. Lancet. 2020;396:535–544. doi: 10.1016/S0140-6736(20)31483-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31483-5</ArticleId><ArticleId IdType="pmc">PMC7336131</ArticleId><ArticleId IdType="pubmed">32645347</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiegand R.E., Deng Y., Deng X., Lee A., Meyer W.A., 3rd, Letovsky S., Charles M.D., Gundlapalli A.V., MacNeil A., Hall A.J., et al. Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-25 October 2020–26 February 2022. Lancet Reg. Health Am. 2023;18:100403. doi: 10.1016/j.lana.2022.100403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lana.2022.100403</ArticleId><ArticleId IdType="pmc">PMC9716971</ArticleId><ArticleId IdType="pubmed">36479424</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernst E., Wolfe P., Stahura C., Edwards K.A. Technical considerations to development of serological tests for SARS-CoV-2. Talanta. 2021;224:121883. doi: 10.1016/j.talanta.2020.121883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.talanta.2020.121883</ArticleId><ArticleId IdType="pmc">PMC7654332</ArticleId><ArticleId IdType="pubmed">33379092</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer K.A., Osorio F.A., Hiscox J.A. Recombinant viral proteins for use in diagnostic ELISAs to detect virus infection. Vaccine. 2007;25:5653–5659. doi: 10.1016/j.vaccine.2007.02.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2007.02.053</ArticleId><ArticleId IdType="pmc">PMC7130988</ArticleId><ArticleId IdType="pubmed">17478017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Woen S., Wang T., Liau B., Zhao S., Chen C., Yang Y., Song Z., Wormald M.R., Yu C., et al. Challenges of glycosylation analysis and control: An integrated approach to producing optimal and consistent therapeutic drugs. Drug Discov. Today. 2016;21:740–765. doi: 10.1016/j.drudis.2016.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2016.01.006</ArticleId><ArticleId IdType="pubmed">26821133</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng X., Duan R.H., Gong F., Wei X., Dong Y., Chen R., Yue Liang M., Tang C., Lu L. Accuracy of serological tests for COVID-19: A systematic review and meta-analysis. Front. Public Health. 2022;10:923525. doi: 10.3389/fpubh.2022.923525.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.923525</ArticleId><ArticleId IdType="pmc">PMC9800917</ArticleId><ArticleId IdType="pubmed">36589993</ArticleId></ArticleIdList></Reference><Reference><Citation>van Tol S., Mogling R., Li W., Godeke G.J., Swart A., Bergmans B., Brandenburg A., Kremer K., Murk J.L., van Beek J., et al. Accurate serology for SARS-CoV-2 and common human coronaviruses using a multiplex approach. Emerg. Microbes Infect. 2020;9:1965–1973. doi: 10.1080/22221751.2020.1813636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1813636</ArticleId><ArticleId IdType="pmc">PMC8284965</ArticleId><ArticleId IdType="pubmed">32819220</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt J., Murugan R., Hippchen T., Olberg S., van Straaten M., Wardemann H., Stebbins E., Krausslich H.G., Bartenschlager R., Brenner H., et al. From Multiplex Serology to Serolomics-A Novel Approach to the Antibody Response against the SARS-CoV-2 Proteome. Viruses. 2021;13:749. doi: 10.3390/v13050749.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050749</ArticleId><ArticleId IdType="pmc">PMC8147094</ArticleId><ArticleId IdType="pubmed">33923338</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape C., Remme R., Wolny A., Olberg S., Wolf S., Cerrone L., Cortese M., Klaus S., Lucic B., Ullrich S., et al. Microscopy-based assay for semi-quantitative detection of SARS-CoV-2 specific antibodies in human sera: A semi-quantitative, high throughput, microscopy-based assay expands existing approaches to measure SARS-CoV-2 specific antibody levels in human sera. Bioessays. 2021;43:e2000257. doi: 10.1002/bies.202000257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.202000257</ArticleId><ArticleId IdType="pmc">PMC7883048</ArticleId><ArticleId IdType="pubmed">33377226</ArticleId></ArticleIdList></Reference><Reference><Citation>Tonshoff B., Muller B., Elling R., Renk H., Meissner P., Hengel H., Garbade S.F., Kieser M., Jeltsch K., Grulich-Henn J., et al. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. JAMA Pediatr. 2021;175:586–593. doi: 10.1001/jamapediatrics.2021.0001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.0001</ArticleId><ArticleId IdType="pmc">PMC7823424</ArticleId><ArticleId IdType="pubmed">33480966</ArticleId></ArticleIdList></Reference><Reference><Citation>Trotard M., Tsopoulidis N., Tibroni N., Willemsen J., Binder M., Ruggieri A., Fackler O.T. Sensing of HIV-1 Infection in Tzm-bl Cells with Reconstituted Expression of STING. J. Virol. 2016;90:2064–2076. doi: 10.1128/JVI.02966-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02966-15</ArticleId><ArticleId IdType="pmc">PMC4733976</ArticleId><ArticleId IdType="pubmed">26656698</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinh T., Jessee J., Bloom F., Hirsch V. STBL2: An Escherichia coli strain for the stable propagation of retroviral clones and direct repeat sequences. Focus. 1994;16:78–80.</Citation></Reference><Reference><Citation>Wang Z., Zhou P., Muecksch F., Cho A., Ben Tanfous T., Canis M., Witte L., Johnson B., Raspe R., Schmidt F., et al. Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans. J. Exp. Med. 2022;219:e20221006. doi: 10.1084/jem.20221006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20221006</ArticleId><ArticleId IdType="pmc">PMC9513381</ArticleId><ArticleId IdType="pubmed">36149398</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt U., Weigert M., Broaddus C., Myers G. Cell Detection with Star-Convex Polygons. Springer International Publishing; Cham, Switzerland: 2018. pp. 265–273.</Citation></Reference><Reference><Citation>Ronneberger O., Fischer P., Brox T. U-Net: Convolutional Networks for Biomedical Image Segmentation. Springer International Publishing; Cham, Switzerland: 2015. pp. 234–241.</Citation></Reference><Reference><Citation>He K., Zhang X., Ren S., Sun J. Deep residual learning for image recognition; Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition; Las Vegas, NV, USA. 27–30 June 2016; pp. 770–778.</Citation></Reference><Reference><Citation>Pape C., Meechan K., Moreva E., Schorb M., Chiaruttini N., Zinchenko V., Martinez Vergara H., Mizzon G., Moore J., Arendt D., et al. MoBIE: A Fiji plugin for sharing and exploration of multi-modal cloud-hosted big image data. Nat. Methods. 2023;20:475–476. doi: 10.1038/s41592-023-01776-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-023-01776-4</ArticleId><ArticleId IdType="pubmed">36765247</ArticleId></ArticleIdList></Reference><Reference><Citation>Chertkova A.O., Mastop M., Postma M., van Bommel N., van der Niet S., Batenburg K.L., Joosen L., Gadella T.W.J., Okada Y., Goedhart J. Robust and Bright Genetically Encoded Fluorescent Markers for Highlighting Structures and Compartments in Mammalian Cells. bioRxiv. 2020:preprints</Citation></Reference><Reference><Citation>Schmidt F., Weisblum Y., Muecksch F., Hoffmann H.H., Michailidis E., Lorenzi J.C.C., Mendoza P., Rutkowska M., Bednarski E., Gaebler C., et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 2020;217:e20201181. doi: 10.1084/jem.20201181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201181</ArticleId><ArticleId IdType="pmc">PMC7372514</ArticleId><ArticleId IdType="pubmed">32692348</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.Y., Huang C., Tian L., Huang X., Zhang C., Llewellyn G.N., Rogers G.L., Andresen K., O’Gorman M.R.G., Chen Y.W., et al. Cytoplasmic Tail Truncation of SARS-CoV-2 Spike Protein Enhances Titer of Pseudotyped Vectors but Masks the Effect of the D614G Mutation. J. Virol. 2021;95:e0096621. doi: 10.1128/JVI.00966-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00966-21</ArticleId><ArticleId IdType="pmc">PMC8549521</ArticleId><ArticleId IdType="pubmed">34495700</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaeta A., Angeloni A., Napoli A., Pucci B., Cinti L., Roberto P., Colaiacovo F., Berardelli E., Farina A., Antonelli G., et al. Anti-N SARS-CoV-2 assays for evaluation of natural viral infection. J. Immunol. Methods. 2023;518:113486. doi: 10.1016/j.jim.2023.113486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2023.113486</ArticleId><ArticleId IdType="pmc">PMC10163944</ArticleId><ArticleId IdType="pubmed">37156408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W., Cheng Y., Zhou H., Sun C., Zhang S. The SARS-CoV-2 nucleocapsid protein: Its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. Virol. J. 2023;20:6. doi: 10.1186/s12985-023-01968-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-023-01968-6</ArticleId><ArticleId IdType="pmc">PMC9831023</ArticleId><ArticleId IdType="pubmed">36627683</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A., Ajithdoss D., Copin R., Zhou A., Lanza K., Negron N., Ni M., Wei Y., Mohammadi K., Musser B., et al. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. Science. 2020;370:1110–1115. doi: 10.1126/science.abe2402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe2402</ArticleId><ArticleId IdType="pmc">PMC7857396</ArticleId><ArticleId IdType="pubmed">33037066</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A., Fulton B.O., Wloga E., Copin R., Pascal K.E., Russo V., Giordano S., Lanza K., Negron N., Ni M., et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369:1014–1018. doi: 10.1126/science.abd0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd0831</ArticleId><ArticleId IdType="pmc">PMC7299283</ArticleId><ArticleId IdType="pubmed">32540904</ArticleId></ArticleIdList></Reference><Reference><Citation>Brehm T.T., Pfefferle S., von Possel R., Karolyi M., Zoufaly A., Wichmann D., Kobbe R., Emmerich P., Norz D., Aepfelbacher M., et al. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants. J. Med. Virol. 2022;94:5038–5043. doi: 10.1002/jmv.27916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27916</ArticleId><ArticleId IdType="pmc">PMC9347884</ArticleId><ArticleId IdType="pubmed">35662058</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruel T., Hadjadj J., Maes P., Planas D., Seve A., Staropoli I., Guivel-Benhassine F., Porrot F., Bolland W.H., Nguyen Y., et al. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies. Nat. Med. 2022;28:1297–1302. doi: 10.1038/s41591-022-01792-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01792-5</ArticleId><ArticleId IdType="pubmed">35322239</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Yisimayi A., Jian F., Song W., Xiao T., Wang L., Du S., Wang J., Li Q., Chen X., et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608:593–602. doi: 10.1038/s41586-022-04980-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04980-y</ArticleId><ArticleId IdType="pmc">PMC9385493</ArticleId><ArticleId IdType="pubmed">35714668</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., Preibisch S., Rueden C., Saalfeld S., Schmid B., et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 2012;9:676–682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou B., Li T.D., Zheng S.F., Su Y.Y., Li Z.Y., Liu W., Yu F., Ge S.X., Zou Q.D., Yuan Q., et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset. Eur. Respir. J. 2020;56 doi: 10.1183/13993003.00763-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00763-2020</ArticleId><ArticleId IdType="pmc">PMC7401320</ArticleId><ArticleId IdType="pubmed">32430429</ArticleId></ArticleIdList></Reference><Reference><Citation>Nair S., Chen X. Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: A systematic review of evidence to support global policy-level actions and research. Glob. Health J. 2022;6:38–43. doi: 10.1016/j.glohj.2021.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.glohj.2021.11.005</ArticleId><ArticleId IdType="pmc">PMC8603838</ArticleId><ArticleId IdType="pubmed">34840854</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J., Deng Y., Zhao Z., Mao B., Lu M., Lin Y., Huang A. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. Cell Mol. Immunol. 2022;19:150–157. doi: 10.1038/s41423-021-00774-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-021-00774-w</ArticleId><ArticleId IdType="pmc">PMC8513558</ArticleId><ArticleId IdType="pubmed">34645940</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki R., Yamasoba D., Kimura I., Wang L., Kishimoto M., Ito J., Morioka Y., Nao N., Nasser H., Uriu K., et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603:700–705. doi: 10.1038/s41586-022-04462-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04462-1</ArticleId><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaku C.I., Bergeron A.J., Ahlm C., Normark J., Sakharkar M., Forsell M.N.E., Walker L.M. Recall of preexisting cross-reactive B cell memory after Omicron BA.1 breakthrough infection. Sci. Immunol. 2022;7:eabq3511. doi: 10.1126/sciimmunol.abq3511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq3511</ArticleId><ArticleId IdType="pmc">PMC9097882</ArticleId><ArticleId IdType="pubmed">35549299</ArticleId></ArticleIdList></Reference><Reference><Citation>Quandt J., Muik A., Salisch N., Lui B.G., Lutz S., Kruger K., Wallisch A.K., Adams-Quack P., Bacher M., Finlayson A., et al. Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes. Sci. Immunol. 2022;7:eabq2427. doi: 10.1126/sciimmunol.abq2427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq2427</ArticleId><ArticleId IdType="pmc">PMC9162083</ArticleId><ArticleId IdType="pubmed">35653438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogier E.W., Giorgi E., Tetteh K., Sepulveda N. Editorial: Current research on serological analyses of infectious diseases. Front. Med. 2023;10:1154584. doi: 10.3389/fmed.2023.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1154584</ArticleId><ArticleId IdType="pmc">PMC9982155</ArticleId><ArticleId IdType="pubmed">36873877</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongkonwattanaporn T., Lertwatcharasarakul P., Rukkwamsuk T. Development of in-house ELISA based on recombinant gag proteins of small ruminant lentiviruses isolated from goats in Thailand. Sci. Rep. 2024;14:3636. doi: 10.1038/s41598-024-54360-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-024-54360-x</ArticleId><ArticleId IdType="pmc">PMC10864301</ArticleId><ArticleId IdType="pubmed">38351130</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietiainen V., Polso M., Migh E., Guckelsberger C., Harmati M., Diosdi A., Turunen L., Hassinen A., Potdar S., Koponen A., et al. Image-based and machine learning-guided multiplexed serology test for SARS-CoV-2. Cell Rep. Methods. 2023;3:100565. doi: 10.1016/j.crmeth.2023.100565.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crmeth.2023.100565</ArticleId><ArticleId IdType="pmc">PMC10475844</ArticleId><ArticleId IdType="pubmed">37671026</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams D.M., Hornsby H.R., Shehata O.M., Brown R., Gallis M., Meardon N., Newman T.A.H., Plowright M., Zafred D., Shun-Shion A.S.M., et al. Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable serological target via high-content microscopy. iScience. 2023;26:107056. doi: 10.1016/j.isci.2023.107056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107056</ArticleId><ArticleId IdType="pmc">PMC10246304</ArticleId><ArticleId IdType="pubmed">37346049</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., McConnell S., Casadevall A., Cappello E., Valdiserra G., Tuccori M. Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect. Dis. 2022;22:e311–e326. doi: 10.1016/S1473-3099(22)00311-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00311-5</ArticleId><ArticleId IdType="pmc">PMC9255948</ArticleId><ArticleId IdType="pubmed">35803289</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor P.C., Adams A.C., Hufford M.M., de la Torre I., Winthrop K., Gottlieb R.L. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 2021;21:382–393. doi: 10.1038/s41577-021-00542-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00542-x</ArticleId><ArticleId IdType="pmc">PMC8054133</ArticleId><ArticleId IdType="pubmed">33875867</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>